Galmed Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

19.09.24	Galmed Pharmaceuticals Stock Is Soaring Thursday: Here's Why (Benzinga)
15.03.24	Galmed Granted European Patent For Use Of Aramchol-Resmetirom To Treat NASH/MASH, Liver Fibrosis (RTTNews)
07.07.22	Galmed: New Data Reinforces Expansion Of Aramchol's Clinical Development To Additional Indications (RTTNews)
19.08.21	Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specific anti-inflammatory compound (PR Newswire)
16.08.21	MHRA Agrees with Galmed's Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study (PR Newswire)
05.08.21	Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results (PR Newswire)
02.08.21	FDA Agrees With Galmed' Plan To Use Aramchol Meglumine In Phase 3 Study; Stock Up (RTTNews)
02.08.21	FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study (PR Newswire)
29.07.21	Galmed Pharmaceuticals to Report Second Quarter 2021 Financial Results and Provide Business Update on Thursday August 5 (PR Newswire)
17.07.20	ACIU'S Alzheimer's Vaccine Study Chugs Along, LCI Up On Distribution Deal, TLSA Hits New High (RTTNews)
16.07.20	GRTX Awaits Pancreatic Cancer Trial Data, GENE Jumps, MNK Gets FDA Panel Backing, TCDA Disappointed (RTTNews)
15.07.20	Stock Alert: Galmed Pharma Shares Up 24% (RTTNews)
31.05.20	Die Expertenmeinungen zur Galmed Pharmaceuticals-Aktie im Mai 2020 (finanzen.net)
31.03.20	März 2020: Experten empfehlen Galmed Pharmaceuticals-Aktie mehrheitlich zum Kauf (finanzen.net)
03.12.19	KOD Dazzles, GLMD On Watch, DRIO Turns Heads… (RTTNews)
31.10.19	Galmed Pharmaceuticals to Present New Data on Aramchol Effect on Glucose Metabolism, MoA and Clinical Results at AASLD 2019 (PR Newswire)
03.08.19	Ausblick: Galmed Pharmaceuticals vermeldet Zahlen zum jüngsten Quartal (finanzen.net)
05.05.19	Ausblick: Galmed Pharmaceuticals legt Zahlen zum jüngsten Quartal vor (finanzen.net)
09.04.19	Galmed Pharmaceuticals Announces Successful Completion of End of Phase 2 Meeting With FDA and Plan for Start of Phase 3 (PR Newswire)
11.03.19	Ausblick: Galmed Pharmaceuticals legt Quartalsergebnis vor (finanzen.net)
13.12.18	GLMD On Watch, ARDS On The Move, MDCO Gets New CEO (RTTNews)
03.11.18	Ausblick: Galmed Pharmaceuticals öffnet die Bücher zum abgelaufenen Quartal (finanzen.net)
18.06.18	Galmed Pharmaceuticals Ltd. Announces Proposed Public Offering of Ordinary Shares (PR Newswire)
13.06.18	GLMD Arrests Investor Attention, SAGE Excited, GEMP On Close Watch (RTTNews)
12.06.18	MÄRKTE USA/Weiter aufwärts mit wenig Elan - Tesla erneut sehr fest (Dow Jones)
12.06.18	MÄRKTE USA/Aufwärtstrend hält an - JPM-Empfehlung treibt Twitter (Dow Jones)
12.06.18	Patience Pays Off For Galmed Investors... (RTTNews)
12.06.18	Galmed's 600 mg Aramchol™ Achieved a Regulatory Approvable Endpoint Showing NASH Resolution Without Worsening of Fibrosis, in NASH Patients, in the Global Phase 2b ARREST 52-Week Study (PR Newswire)
12.06.18	Galmed's 600 mg Aramchol™ Achieved a Regulatory Approvable Endpoint Showing NASH Resolution Without Worsening of Fibrosis, in NASH Patients, in the Global Phase 2b ARREST 52-Week Study (PR Newswire)
11.06.18	Galmed Pharmaceuticals to Host Conference Call to Discuss Top-Line, 52-Week Results from the Global Phase 2b ARREST Study (PR Newswire)
09.05.18	Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2018 Financial Results (PR Newswire)
01.05.18	New York REIT, Inc. Declares a $4.85 Per Share Cash Liquidating Distribution (PR Newswire)
01.05.18	Galmed Pharmaceuticals to Report First Quarter 2018 Financial Results and Provide Business Update on Wednesday, May 9 (PR Newswire)
16.04.18	Galmed Pharmaceuticals to Host Post-EASL Key Opinion Leader Call on the Scientific Rationale and Clinical Development of Aramchol™ for NASH (PR Newswire)
03.04.18	Top Chinese Logistics Robot Maker Geek+ Debuts at MODEX (PR Newswire)
27.03.18	Galmed Pharmaceuticals to Present New Scientific Data on the Mechanism by Which Aramchol Exerts its Effect on Fibrosis at EASL (PR Newswire)
13.03.18	Galmed Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update (PR Newswire)
05.03.18	Galmed Pharmaceuticals to Report Full Year and Fourth Quarter 2017 Financial Results and Provide Business Update on Tuesday, March 13 (PR Newswire)
02.03.18	Galmed Pharmaceuticals to Participate in Investor Conferences in March (PR Newswire)
16.02.18	FDA To Decide On APRI's ED Drug, KURA Nails It, MBRX Dynamic, GLMD Awaits ARREST (RTTNews)
15.02.18	AMAG Gets FDA Nod, ABMD Hits All-time High, GLMD's NAFLD Trial Flops, NKTR Abuzz (RTTNews)
14.02.18	Galmed Announces ARRIVE Study Data (PR Newswire)
08.02.18	Galmed Pharmaceuticals to Provide Corporate Update at the LEERINK Partners 7th Annual Global Healthcare Conference (PR Newswire)
07.02.18	Galmed Granted "Preferred Technological Enterprise" Status Which may Provide the Company With Significant Financial Benefits (PR Newswire)
16.01.18	The Race To Find A Treatment For NASH (RTTNews)
02.01.18	Galmed Pharmaceuticals Raised Gross Proceeds of $11.6 Million Under ATM Programs During December 2017 (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Galmed Pharmaceuticals Ltd.

Aktien Top/Flop

Meistgelesene Nachrichten